NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, ...

The pharma major said it faces the largest drug-patent expiry headwind in its history this year.

Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...

Novartis has core profit growth, buybacks, seven clinical readouts, a 5% dividend hike, generic competition, and a 54% FCF ...

Novartis forecast its first annual drop in operating profit in a decade on Wednesday, even as it indicated that long term, the company could potentially offset ‍the patent expiry of its ...

MSN Laboratories Pvt. Ltd. can’t reopen disputes resolved in earlier litigation over the scope, validity, and infringement of ...

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...

After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp.

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. REUTERS/Arnd Wiegmann/File Photo FRANKFURT (Reuters) -Swiss drugmaker ...

By Ludwig Burger and Bhanvi Satija FRANKFURT, Feb 4 (Reuters) - Swiss drugmaker Novartis forecast a worse-than-expected ...